Short-Term and Long-Term Outcomes After Polytetrafluoroethylene-Covered Stent Implantation for the Treatment of Coronary Perforation

详细信息    查看全文

• 作者：Hiroyoshi Kawamoto ; MD^a ; ^{hrys23@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Kentaro Tanaka ; MD^a ; Neil Ruparelia ; MBBS ; DPhil ; MRCP^b ; Kensuke Takagi ; MD^a ; Hiroto Yabushita ; MD^a ; Yusuke Watanabe ; MD^a ; Satoru Mitomo ; MD^a ; Takahiro Matsumoto ; MD^a ; Toru Naganuma ; MD^a ; Yusuke Fujino ; MD ; PhD^a ; Hisaaki Ishiguro ; MD ; PhD^a ; Satoko Tahara ; MD ; PhD^a ; Naoyuki Kurita ; MD^a ; Shotaro Nakamura ; MD^a ; Koji Hozawa ; MD^a ; Sunao Nakamura ; MD ; PhD^a
• 刊名：The American Journal of Cardiology
• 出版年：2015
• 出版时间：15 December 2015
• 年：2015
• 卷：116
• 期：12
• 页码：1822-1826
• 全文大小：391 K

文摘

This study sought to evaluate the short-term and 3-year outcomes of polytetrafluoroethylene-covered stent (PCS) for patients with coronary perforation. Implantation of a PCS has improved the immediate clinical outcomes of patients with coronary perforation. However, there are few reports regarding long-term outcomes. We evaluated a total of 57 patients who were treated with PCS for coronary perforation from April 2004 to March 2015 at a single high-volume center in Japan. Landmark analysis was performed at 30 days to determine short-term and long-term outcomes. Major adverse cardiac events (MACE) were defined as death, myocardial infarction, target vessel revascularization, and requirement for surgical repair. Of 285 patients who experienced coronary perforation, 57 patients (20%) were treated with PCS. The MACE rates were 28% at 30 days, 22% at 1 year, and 38% at 3 years. 30-day MACE was mainly driven by high rates of myocardial infarction (18%) and surgical repair (16%). The rates of target lesion revascularization were 8% and 12% at 1 and 3 years, respectively. Definite stent thrombosis was reported in 2 patients during the follow-up period. In conclusion, despite the relatively high incidence of MACE during early stage of follow-up, implantation of a PCS provides acceptable late clinical outcomes.